research Direct-Acting Vasodilators
Hydralazine and minoxidil are blood pressure medications that relax blood vessels, with potential side effects like rapid heartbeat and fluid retention, and are used for severe or pregnancy-related hypertension.
Search
for
Sort by
Research
150-180 / 1000+ results
research Oral medications for central serous chorioretinopathy: a literature review
Some oral medications may help treat central serous chorioretinopathy, especially eplerenone, but more research is needed.
research Ion pairs of risedronate for transdermal delivery and enhanced permeation rate on hairless mouse skin
Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis
Avacopan is generally safe, with some minor side effects like nausea and fatigue.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research TGF-β Signaling: a Potential Therapeutic Target of Single Herbs and Extracts for Renal Fibrosis
Certain Chinese herbs may help treat kidney fibrosis by targeting TGF-β.
research Errata
The document corrects errors in previous articles, including a reversed term, updated subject weights, hair count data, and reference numbering.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
research WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
research Adverse Effects and Drug Interactions of Biologic Agents
Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
research Ivarmacitinib stimulates hair regrowth in severe alopecia areata
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research 5α-reductase inhibitors impact prognosis of urothelial carcinoma
5α-reductase inhibitors may lower the risk of death from bladder cancer.
research Minoxidil
Minoxidil effectively treats severe hypertension but has notable side effects.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research 0955 Selective BET inhibition as potential hidradenitis suppurativa treatment
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
research Studying the correlation of renin-angiotensin-system (RAS) components and insulin resistance in polycystic ovary syndrome (PCOs)
The study found a significant link between the renin-angiotensin system and insulin resistance in women with polycystic ovary syndrome.
research Citrate Anticoagulation in Hemodialysis
Citrate is a safer alternative to heparin for preventing blood clots in hemodialysis.
research Long-Term Treatment of Refractory Hypertensive Patients With Minoxidil
Minoxidil controls blood pressure but may cause kidney damage and needs diuretics to prevent swelling.
research Abiraterone and spironolactone in prostate cancer: a combination to avoid
Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.